| Year |
Citation |
Score |
| 2020 |
Oberheim Bush NA, Yu Y, Villanueva-Meyer J, Grimmer M, Hilz S, Solomon D, Choi S, Mazor T, Hong C, Shai A, Phillips JJ, McDermott M, Haas-Kogan DA, Taylor J, Butowski NA, ... ... Berger M, et al. Temozolomide-induced hypermutation is associated with high-grade transformation, distant recurrence, and reduced survival after transformation in initially low-grade IDH-mutant diffuse gliomas. Journal of Clinical Oncology. 38: 2506-2506. DOI: 10.1200/Jco.2020.38.15_Suppl.2506 |
0.357 |
|
| 2020 |
Hervey-Jumper S, Molinaro A, Phillips J, Morshed R, Young J, Zhang Y, LaFontaine M, Luks T, Ammanuel S, Kakaizada S, Villanueva-Meyer J, Shai A, Warrier G, Rice T, Lin Y, ... ... Berger M, et al. SURG-15. A NOVEL RISK MODEL TO DEFINE THE RELATIVE BENEFIT OF MAXIMAL EXTENT OF RESECTION WITHIN PROGNOSTIC GROUPS IN NEWLY DIAGNOSED DIFFUSE LOW-GRADE GLIOMA Neuro-Oncology. 22: ii206-ii206. DOI: 10.1093/neuonc/noaa215.862 |
0.304 |
|
| 2019 |
Lucas CG, Villanueva-Meyer JE, Whipple N, Oberheim Bush NA, Cooney T, Chang S, McDermott M, Berger M, Cham E, Sun PP, Putnam A, Zhou H, Bollo R, Cheshier S, Poppe MM, et al. Myxoid glioneuronal tumor, PDGFRA p.K385-mutant: clinical, radiologic, and histopathologic features. Brain Pathology (Zurich, Switzerland). PMID 31609499 DOI: 10.1111/Bpa.12797 |
0.392 |
|
| 2019 |
De Witte E, Piai V, Kurteff G, Cai R, Mariën P, Dronkers N, Chang E, Berger M. A valid alternative for in-person language assessments in brain tumor patients: feasibility and validity measures of the new TeleLanguage test. Neuro-Oncology Practice. 6: 93-102. PMID 31386040 DOI: 10.1093/Nop/Npy020 |
0.321 |
|
| 2019 |
Chandra A, Oh T, Wadhwa H, Shah S, Gupta N, McDermott M, Berger M, Aghi M. RARE-30. PEDIATRIC GLIOBLASTOMA IN THE POST-TEMOZOLOMIDE ERA: OUTCOMES AND CHARACTERISTICS Neuro-Oncology. 21: vi227-vi228. DOI: 10.1093/Neuonc/Noz175.953 |
0.385 |
|
| 2019 |
Young J, Zhang Y, Molinaro A, Taylor J, Clarke J, Prados M, Chang S, Berger M, Butowski N, Ann Oberheim-Bush N. RTHP-33. A SINGLE INSTITUTION RETROSPECTIVE ANALYSIS ON SURVIVAL BASED ON TREATMENT PARADIGMS FOR PATIENTS WITH ANAPLASTIC OLIGODENDROGLIOMA Neuro-Oncology. 21: vi216-vi217. DOI: 10.1093/Neuonc/Noz175.904 |
0.332 |
|
| 2019 |
Chandra A, Kanungo I, Rick J, Yue J, Dayani F, Nguyen A, Flanigan P, Chang E, McDermott M, Berger M, Aghi M. QOLP-27. CLINICAL FACTORS AND MOLECULAR MARKERS ASSOCIATED WITH POSTOPERATIVE SEIZURES IN GLIOBLASTOMA Neuro-Oncology. 21: vi203-vi203. DOI: 10.1093/Neuonc/Noz175.847 |
0.301 |
|
| 2019 |
Calixto-Hope L, Lee J, Sloan E, Hofmann J, Van Ziffle J, Onodera C, Grenert J, Devine P, Kline C, Banerjee A, Clarke J, Taylor J, Ann Oberheim-Bush N, Buerki R, Butowski N, ... ... Berger M, et al. PATH-38. ROSETTE-FORMING GLIONEURONAL TUMOR IS DEFINED BY FGFR1 ACTIVATING ALTERATIONS WITH FREQUENT ACCOMPANYING PI3K AND MAPK PATHWAY MUTATIONS Neuro-Oncology. 21: vi151-vi152. DOI: 10.1093/Neuonc/Noz175.634 |
0.314 |
|
| 2019 |
Zhang M, Hilz S, Martin M, Hong C, Yu Y, Bollam S, Grimmer M, Looney T, Lowman G, Ganpule G, Phillips J, Shai A, Chang S, Clarke J, Taylor J, ... ... Berger M, et al. IMMU-11. SPATIOTEMPORAL IMMUNOGENOMIC ANALYSIS OF THE T-CELL REPERTOIRE IN IDH-MUTANT LOWER GRADE GLIOMAS Neuro-Oncology. 21: vi121-vi121. DOI: 10.1093/Neuonc/Noz175.505 |
0.332 |
|
| 2019 |
Hilz S, Hong C, Jalbert L, Mazor T, Martin M, Kumar A, Shelton S, Wong K, Hayes J, Yu Y, Zhang M, Luks T, Olson M, Lafontaine M, Shai A, ... ... Berger M, et al. GENE-47. A 3D ATLAS TO EVALUATE THE SPATIAL PATTERNING OF GENETIC ALTERATIONS AND TUMOR CELL STATES IN GLIOMA Neuro-Oncology. 21: vi107-vi108. DOI: 10.1093/Neuonc/Noz175.449 |
0.372 |
|
| 2019 |
John Liu S, Vasudevan H, Pekmezci M, Choudhury A, Lien B, Breshears J, Swaney D, Magill S, Lang U, Chen W, Gopinath C, Castro M, Villanueva-Meyer J, Braunstein S, Sneed P, ... ... Berger M, et al. GENE-37. VESTIBULAR SCHWANNOMA IS COMPRISED OF NEURAL CREST AND IMMUNE SUBGROUPS Neuro-Oncology. 21: vi105-vi105. DOI: 10.1093/Neuonc/Noz175.439 |
0.347 |
|
| 2019 |
Mathur R, Zhang Y, Grimmer M, Hong C, Berger M, Molinaro A, Ann Oberheim-Bush N, Chang S, Costello J. GENE-35. MGMT PROMOTER METHYLATION IN NEWLY DIAGNOSED LGG AS A POTENTIAL BIOMARKER FOR TMZ-ASSOCIATED HYPERMUTATION AT RECURRENCE Neuro-Oncology. 21: vi105-vi105. DOI: 10.1093/Neuonc/Noz175.437 |
0.364 |
|
| 2019 |
Magill S, Vasudevan H, Seo K, John Liu S, Hilz S, Villanueva-Meyer J, Choudhury A, Demaree B, Lim D, Braunstein S, Ann Oberheim-Bush N, Ullian E, Aghi M, Theodosopoulos P, Sneed P, ... ... Berger M, et al. TMOD-27. A NEURAL CREST CELL SUBPOPULATION UNDERLIES INTRATUMOR HETEROGENEITY IN MENINGIOMA Neuro-Oncology. 21: vi268-vi268. DOI: 10.1093/Neuonc/Noz175.1126 |
0.322 |
|
| 2019 |
Krishna S, Kakaizada S, Valdivia C, Seo K, Raleigh D, Findlay A, Almeida N, Sudharshan R, Choudhury A, Brang D, Nagarajan S, Berger M, Monje M, Hervey-Jumper S. TMIC-46. GLIOMA-INDUCED SYNAPTOGENESIS IS ENRICHED WITHIN FUNCTIONAL CONNECTIVITY NETWORK HUBS AND INFLUENCES LANGUAGE PROCESSING IN ADULT IDH WT GLIOBLASTOMA Neuro-Oncology. 21: vi257-vi258. DOI: 10.1093/Neuonc/Noz175.1080 |
0.3 |
|
| 2019 |
Taylor J, Molinaro A, Rodriguez Almaraz E, Downey C, Phillips J, Ann Oberheim-Bush N, Butowski N, Chang S, Berger M, Prados M, Haas-Kogan D, Clarke J. ACTR-42. PI3K/mTOR PATHWAY ACTIVATION SELECTED PHASE II STUDY OF EVEROLIMUS (RAD001) WITH AND WITHOUT TEMOZOLOMIDE IN THE TREATMENT OF ADULT PATIENTS WITH SUPRATENTORIAL LOW-GRADE GLIOMA [NCT NCT02023905] Neuro-Oncology. 21: vi22-vi23. DOI: 10.1093/Neuonc/Noz175.084 |
0.353 |
|
| 2019 |
Morshed R, Reihl S, Kakaizada S, Zhang E, Young J, Clarke J, Butowski N, Taylor J, Ann Oberheim-Bush N, Aghi M, Berger M, Chang S, Hervey-Jumper S. ACTR-35. A STUDY OF RACE AND SOCIOECONOMIC STATUS IMPACTING THERAPEUTIC CLINICAL TRIAL ENROLLMENT IN ADULT GLIOMAS PATIENTS Neuro-Oncology. 21: vi21-vi21. DOI: 10.1093/Neuonc/Noz175.078 |
0.319 |
|
| 2018 |
López GY, Van Ziffle J, Onodera C, Grenert JP, Yeh I, Bastian BC, Clarke J, Oberheim Bush NA, Taylor J, Chang S, Butowski N, Banerjee A, Mueller S, Kline C, Torkildson J, ... Berger M, et al. The genetic landscape of gliomas arising after therapeutic radiation. Acta Neuropathologica. PMID 30196423 DOI: 10.1007/S00401-018-1906-Z |
0.371 |
|
| 2018 |
Pekmezci M, Villanueva-Meyer JE, Goode B, Van Ziffle J, Onodera C, Grenert JP, Bastian BC, Chamyan G, Maher OM, Khatib Z, Kleinschmidt-DeMasters BK, Samuel D, Mueller S, Banerjee A, Clarke JL, ... Berger M, et al. The genetic landscape of ganglioglioma. Acta Neuropathologica Communications. 6: 47. PMID 29880043 DOI: 10.1186/S40478-018-0551-Z |
0.302 |
|
| 2018 |
Dayani F, Young JS, Bonte A, Chang EF, Theodosopoulos P, McDermott MW, Berger MS, Aghi MK. Safety and outcomes of resection of butterfly glioblastoma. Neurosurgical Focus. 44: E4. PMID 29852771 DOI: 10.3171/2018.3.FOCUS1857 |
0.306 |
|
| 2018 |
Morshed RA, Young JS, Han SJ, Hervey-Jumper SL, Berger MS. The transcortical equatorial approach for gliomas of the mesial temporal lobe: techniques and functional outcomes. Journal of Neurosurgery. 1-9. PMID 29676697 DOI: 10.3171/2017.10.JNS172055 |
0.303 |
|
| 2015 |
Barajas RF, Pampaloni MH, Clarke JL, Seo Y, Savic D, Hawkins RA, Behr SC, Chang SM, Berger M, Dillon WP, Cha S. Assessing Biological Response to Bevacizumab Using 18F-Fluoromisonidazole PET/MR Imaging in a Patient with Recurrent Anaplastic Astrocytoma. Case Reports in Radiology. 2015: 731361. PMID 25793136 DOI: 10.1155/2015/731361 |
0.335 |
|
| 2015 |
Claus EB, Walsh KM, Wiencke JK, Molinaro AM, Wiemels JL, Schildkraut JM, Bondy ML, Berger M, Jenkins R, Wrensch M. Survival and low-grade glioma: the emergence of genetic information. Neurosurgical Focus. 38: E6. PMID 25552286 DOI: 10.3171/2014.10.Focus12367 |
0.39 |
|
| 2015 |
Shelton S, Johnson B, Mazor T, Potts M, McDermott M, Huang E, Lim D, Pieper R, Berger M, Phillips J, Costello J, Oldham M. MPTH-29CONNECTING MUTANT GENOTYPES TO ABERRANT TRANSCRIPTIONAL SIGNATURES ACROSS SERIAL SECTIONS OF A HUMAN TUMOR Neuro-Oncology. 17: v144.4-v145. DOI: 10.1093/Neuonc/Nov222.29 |
0.364 |
|
| 2015 |
Mazor T, Johnson BE, Grimmer M, Hong C, Hamilton EG, Jones LE, Xavier-Magalhães A, Smirnov IV, Bengtsson H, Olshen AB, Petrecca K, Bollen AW, Berger MS, Taylor BS, Nelson SJ, et al. GENO-25HYPERMUTATION AND MALIGNANT PROGRESSION IN AN EXPANDED COHORT OF TEMOZOLOMIDE-TREATED LOW-GRADE GLIOMA PATIENTS Neuro-Oncology. 17: v97.1-v97. DOI: 10.1093/Neuonc/Nov215.25 |
0.306 |
|
| 2015 |
Walsh K, Pekmezci M, Decker P, Hansen H, Sicotte H, Rice T, Kollmeyer T, McCoy L, Sarkar G, Perry A, Giannini C, Tihan T, Berger M, Molinaro A, Wiemels J, et al. EPID-31ATRX AND TERT ASSAYS PROVIDE NON-REDUNDANT INFORMATION IN ADULT GLIOMA PATIENTS: INCORPORATING TELOMERE MARKERS INTO NEUROPATHOLOGY PRACTICE Neuro-Oncology. 17: v85.1-v85. DOI: 10.1093/Neuonc/Nov213.31 |
0.411 |
|
| 2015 |
Wahl M, Aicardi J, Molinaro A, Haas-Kogan D, Butowski N, Clarke J, Prados M, Phillips J, Berger M, Chang S. ATCT-32A PHASE II STUDY OF TEMOZOLOMIDE IN THE TREATMENT OF ADULT PATIENTS WITH SUPRATENTORIAL LOW-GRADE GLIOMA Neuro-Oncology. 17: v8.4-v9. DOI: 10.1093/Neuonc/Nov206.32 |
0.363 |
|
| 2015 |
Lau D, Hervey-Jumper S, Chang S, Molinaro A, McDermott M, Phillips J, Berger M. ATCT-21A PROSPECTIVE PHASE II CLINICAL TRIAL OF 5-AMINOLEVULINIC ACID TO CORRELATE INTRAOPERATIVE FLUORESCENCE INTENSITY WITH HISTOLOGIC CELLULARITY Neuro-Oncology. 17: v6.1-v6. DOI: 10.1093/Neuonc/Nov206.21 |
0.368 |
|
| 2015 |
Iikhanizadeh S, Miroshnikova Y, Frantz A, Zhu W, Idilli A, Quigley D, Lakins J, Magnitsky S, Phillips J, James D, Berger M, Arosio D, Sun D, Weaver V, Weiss W, et al. ATPS-63OSMOTIC SWELLING REGULATES TUMOR GROWTH AND DRUG UPTAKE IN HUMAN GLIOBLASTOMA Neuro-Oncology. 17: v32.1-v32. DOI: 10.1093/Neuonc/Nov204.63 |
0.345 |
|
| 2014 |
Hervey-Jumper SL, Berger MS. Role of surgical resection in low- and high-grade gliomas. Current Treatment Options in Neurology. 16: 284. PMID 24595756 DOI: 10.1007/s11940-014-0284-7 |
0.311 |
|
| 2014 |
Ilkhanizadeh S, Miroshnikova Y, Frantz A, James D, Berger M, McKnight T, Weaver V, Weiss W, Persson A. NT-11 * TARGETING INTERSTITIAL FLUID PRESSURE TO REDUCE TUMOR GROWTH AND INCREASE DRUG UPTAKE IN BRAIN TUMORS Neuro-Oncology. 16: v161-v161. DOI: 10.1093/Neuonc/Nou265.11 |
0.367 |
|
| 2014 |
Hervey-Jumper S, Li J, Lau D, Molinaro A, Perry D, Meng L, Berger M. NC-06 * AWAKE CRANIOTOMY TO MAXIMIZE GLIOMA RESECTION: METHODS AND TECHNICAL NUANCES Neuro-Oncology. 16: v135-v135. DOI: 10.1093/Neuonc/Nou263.6 |
0.396 |
|
| 2014 |
Nagarajan R, Barajas R, Mazor T, Phillips J, Ma J, Hong C, Johnson B, Dayal M, Cha S, Nakamura J, Berger M, Chang S, Furnari F, Taylor B, Costello J. GE-42 * INTEGRATED RADIOGRAPHIC AND PHYLOGENETIC CASE STUDY OF A PRIMARY AND CONTRALATERAL RECURRENT GLIOMA Neuro-Oncology. 16: v105-v106. DOI: 10.1093/Neuonc/Nou256.41 |
0.383 |
|
| 2014 |
Johnson B, Mazor T, Hong C, Barnes M, Yamamoto S, Ueda H, Tatsuno K, Aihara K, Asthana S, Dayal M, Nelson S, Phillips J, Bollen A, Mukasa A, Saito N, ... ... Berger M, et al. GE-15 * CLONAL EVOLUTION AND INTRATUMORAL HETEROGENEITY OF LOW-GRADE GLIOMA GENOMES Neuro-Oncology. 16: v99-v99. DOI: 10.1093/Neuonc/Nou256.15 |
0.406 |
|
| 2014 |
Han S, Martin A, Berger M, Prados M, Chang S, Clarke J, Bankiewicz K, Butowski N. AT-25 * A PHASE I STUDY OF CONVECTION-ENHANCED DELIVERY OF LIPOSOMAL-IRINOTECAN USING REAL-TIME IMAGING WITH GADOLINIUM IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA Neuro-Oncology. 16: v14-v14. DOI: 10.1093/Neuonc/Nou237.25 |
0.315 |
|
| 2014 |
Clarke JL, Chang S, Phillips J, Molinaro A, Berger M, Nelson S, Haas-Kogan D. EVEROLIMUS (RAD001) AND THE MTOR PATHWAY IN LOW-GRADE GLIOMAS Neuro-Oncology. 16: iii48-iii48. DOI: 10.1093/Neuonc/Nou209.24 |
0.425 |
|
| 2013 |
Safaee M, Clark AJ, Bloch O, Oh MC, Singh A, Auguste KI, Gupta N, McDermott MW, Aghi MK, Berger MS, Parsa AT. Surgical outcomes in choroid plexus papillomas: an institutional experience. Journal of Neuro-Oncology. 113: 117-25. PMID 23468001 DOI: 10.1007/s11060-013-1097-3 |
0.309 |
|
| 2013 |
Hiniker A, Lee HS, Chang S, Berger M, Perry A. Cortical ependymoma with unusual histologic features. Clinical Neuropathology. 32: 318-23. PMID 23458270 DOI: 10.5414/Np300593 |
0.314 |
|
| 2012 |
Butowski NA, Berger M. Malignant Gliomas: Part I Contemporary Neurosurgery. 34: 1-5. DOI: 10.1097/01.Cne.0000413591.22318.C0 |
0.318 |
|
| 2006 |
Rubenstein JL, Fridlyand J, Shen A, Aldape K, Ginzinger D, Batchelor T, Treseler P, Berger M, McDermott M, Prados M, Karch J, Okada C, Hyun W, Parikh S, Haqq C, et al. Gene expression and angiotropism in primary CNS lymphoma. Blood. 107: 3716-23. PMID 16418334 DOI: 10.1182/Blood-2005-03-0897 |
0.329 |
|
| 2005 |
Wrensch M, Fisher JL, Schwartzbaum JA, Bondy M, Berger M, Aldape KD. The molecular epidemiology of gliomas in adults. Neurosurgical Focus. 19: E5. PMID 16398469 DOI: 10.3171/Foc.2005.19.5.6 |
0.386 |
|
| 2005 |
Parney IF, Kunwar S, McDermott M, Berger M, Prados M, Cha S, Croteau D, Puri RK, Chang SM. Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma. Journal of Neurosurgery. 102: 267-75. PMID 15739554 DOI: 10.3171/Jns.2005.102.2.0267 |
0.363 |
|
| 2004 |
Larson DA, Suplica JM, Chang SM, Lamborn KR, McDermott MW, Sneed PK, Prados MD, Wara WM, Nicholas MK, Berger MS. Permanent iodine 125 brachytherapy in patients with progressive or recurrent glioblastoma multiforme Neuro-Oncology. 6: 119-126. PMID 15134626 DOI: 10.1215/S1152851703000425 |
0.304 |
|
| 2003 |
Prados MD, McDermott M, Chang SM, Wilson CB, Fick J, Culver KW, Van Gilder J, Keles GE, Spence A, Berger M. Treatment of progressive or recurrent glioblastoma multiforme in adults with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration: A phase I/II multi-institutional trial Journal of Neuro-Oncology. 65: 269-278. PMID 14682377 DOI: 10.1023/B:Neon.0000003588.18644.9C |
0.351 |
|
| 2003 |
Weber F, Asher A, Bucholz R, Berger M, Prados M, Chang S, Bruce J, Hall W, Rainov NG, Westphal M, Warnick RE, Rand RW, Floeth F, Rommel F, Pan H, et al. Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma. Journal of Neuro-Oncology. 64: 125-37. PMID 12952293 DOI: 10.1007/Bf02700027 |
0.333 |
|
| 2003 |
Chang SM, Parney IF, McDermott M, Barker FG, Schmidt MH, Huang W, Laws ER, Lillehei KO, Bernstein M, Brem H, Sloan AE, Berger M. Perioperative complications and neurological outcomes of first and second craniotomies among patients enrolled in the Glioma Outcome Project. Journal of Neurosurgery. 98: 1175-81. PMID 12816260 DOI: 10.3171/Jns.2003.98.6.1175 |
0.352 |
|
| 2002 |
Berger M, Char DH. Interactive image guidance for surgical localization of orbital apical tumors. Orbit (Amsterdam, Netherlands). 21: 199-203. PMID 12187413 DOI: 10.1076/Orbi.21.3.199.7180 |
0.338 |
|
| 2001 |
Hirose Y, Aldape K, Bollen A, James CD, Brat D, Lamborn K, Berger M, Feuerstein BG. Chromosomal abnormalities subdivide ependymal tumors into clinically relevant groups American Journal of Pathology. 158: 1137-1143. PMID 11238062 DOI: 10.1016/S0002-9440(10)64061-8 |
0.325 |
|
| 2001 |
Asher AL, Weber F, Bucholz R, Berger M, Prados M, Bruce J, Hall W, Rainov NG, Westphal M, Warnick R, Williams RL, Hingorani VN, Puri RK. 763 Safety, Tolerability and Tumor Response of IL4-toxin (NBI-3001) in Patients with Recurrent Malignant Glioma Neurosurgery. 49: 525-525. DOI: 10.1097/00006123-200108000-00127 |
0.348 |
|
| 1996 |
Skirboll SS, Ojemann GA, Berger MS, Lettich E, Winn HR. Functional cortex and subcortical white matter located within gliomas. Neurosurgery. 38: 678-84; discussion 6. PMID 8692384 DOI: 10.1227/00006123-199604000-00008 |
0.371 |
|
| 1994 |
Morrison RS, Yamaguchi F, Saya H, Bruner JM, Yahanda AM, Donehower LA, Berger M. Basic fibroblast growth factor and fibroblast growth factor receptor I are implicated in the growth of human astrocytomas. Journal of Neuro-Oncology. 18: 207-16. PMID 7964981 DOI: 10.1007/Bf01328955 |
0.329 |
|
| 1994 |
Rostomily RC, Spence AM, Duong D, McCormick K, Bland M, Berger MS. Multimodality management of recurrent adult malignant gliomas: results of a phase II multiagent chemotherapy study and analysis of cytoreductive surgery. Neurosurgery. 35: 378-88; discussion 3. PMID 7800129 DOI: 10.1227/00006123-199409000-00004 |
0.323 |
|
| 1992 |
Bourne JP, Geyer R, Berger M, Griffin B, Milstein J. The prognostic significance of postoperative residual contrast enhancement on CT scan in pediatric patients with medulloblastoma. Journal of Neuro-Oncology. 14: 263-70. PMID 1460489 DOI: 10.1007/Bf00172602 |
0.347 |
|
| 1985 |
Pertuiset B, Dougherty D, Cromeyer C, Hoshino T, Berger M, Rosenblum ML. Stem cell studies of human malignant brain tumors. Part 2: Proliferation kinetics of brain-tumor cells in vitro in early-passage cultures. Journal of Neurosurgery. 63: 426-432. PMID 4020471 DOI: 10.3171/Jns.1985.63.3.0426 |
0.35 |
|
| Show low-probability matches. |